96 3.1. Impacts biologiques de l'interaction médicamenteuse, p.96 ,
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-Inhibiting Medications ,
Moderate alcohol intake and cancer incidence in women ,
Chirurgie en prévention des cancers du sein. Chez les femmes à risque familial ayant une mutation délétère d'un gène BRCA ,
Les cancers du sein chez la femme Une évolution naturelle et un pronostic très variables d'une femme à l'autre ,
Les effets indésirables des mammographies de dépistage des cancers du sein ,
Torémifène et cancer du sein. Pas d'avantage démontré sur le tamoxifène ,
Therapy for menopausal symptoms during and after treatment for breast cancer: safety considerations ,
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors ,
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial, Lancet, vol.359, pp.2131-3139, 2002. ,
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, pp.1802-1810, 2003. ,
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial ,
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer, pp.2247-2258, 2001. ,
Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review ,
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment ,
Postmenopausal Breast Cancer Risk and Cumulative Number of Menstrual Cycles, Cancer Epidemiology Biomarkers & Prevention, vol.14, issue.4, pp.799-804, 2005. ,
DOI : 10.1158/1055-9965.EPI-04-0465
Breast cancer recurrence risk in relation to antidepressant use after diagnosis, Breast Cancer Res Treat, vol.112, pp.123-132, 2008. ,
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer ,
Classification des lésions pré-invasives et des carcinomes in situ : doutes, controverses, proposition de nouvelles classifications, Bull Cancer, vol.91, pp.205-210, 2004. ,
Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects, Bull Cancer, vol.91, pp.917-927, 2004. ,
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer ,
Adult weight change and risk of postmenopausal breast cancer ,
Major depression after breast cancer: a review of epidemiology and treatment ,
Five versus more than five years of tamoxifen for lymph node-negative breast cancer : updated findings from the national Surgical Adjuvant Breast and Bowel Project B-14 randomized trial ,
A pratical guide to the management of menopausal symptoms in breast cancer patients. Support Care Cancer, pp.573-578, 2005. ,
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen, Breast Cancer Res Treat, vol.101, pp.113-121, 2007. ,
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes ,
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression, Am J Psychiatry, vol.165, pp.1251-1255, 2008. ,
Management of menopausal symptoms in patients with breast cancer: an evidence-based approach ,
Pharmacokinetics of selective serotonin reuptake inhibitors ,
of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer, Lancet, vol.365, pp.60-62, 2005. ,
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, pp.double-blind ,
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects ,
Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, Lancet, vol.366, pp.455-462, 2005. ,
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment ,
Pharmacological characterization of 4- hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen, Breast Cancer Res Treat, vol.85, pp.151-159, 2004. ,
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study ,
Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen ,
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy ,
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials ,
Approche neurobiologique de la dépression : nouvelles données ,
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen ,
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram ,
Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy ,
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial ,
Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition ,
Excellent outcomes with adjuvant toremifen or tamoxifen in early stage breast cancer. Cancer, pp.2307-2315, 2010. ,
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer ,
Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen ,
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells ,
Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine ,
Phase III evaluation of fluoxetine for treatment of hot flashes ,
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and nonvisceral metastases: combined results from two multicentre trials ,
Pharmacokinetics of selective estrogen receptor modulators ,
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial ,
Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy, Breast Cancer Res Treat, vol.112, pp.197-201, 2008. ,
Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis ,
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer ,
Association between CP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen ,
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update ,
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine ,
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial ,
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer ,
Sertraline effectiveness and safety in depressed oncological patients. Support Care Cancer, pp.83-91, 2008. ,
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma ,
Cancer du sein chez la femme, incidence et mortalité, 2000. ,
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer, Breast Cancer Res, vol.9, p.7, 2007. ,
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients, Breast Cancer Res, vol.7, pp.284-290, 2005. ,
The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review ,
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells ,
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment ,
Mode d'action du tamoxifène et résistance au tamoxifène ,
Le sein du normal au pathologique : état de l'art, pp.943-952, 2007. ,
Histologie du sein Le sein du normal au pathologique : état de l'art, Editions Eska, pp.54-59, 2007. ,
Tumeurs malignes du sein .Tumeurs rares Le sein du normal au pathologique : état de l'art, Editions Eska, pp.367-377, 2007. ,
Le sein du normal au pathologique : état de l'art, Editions Eska, pp.565-590, 2007. ,
eMedicine web-site : http://emedicine.medscape.com/article/283561-overview Mai 2010 [109] Europa Donna France web-site : http://www.europadonna.fr/_cancers_du_sein/page_accueil_cancers_sein, 2000. ,